We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 40% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
At this time, Editas has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Mirum Pharmaceuticals, Inc. (MIRM - Free Report) , has gained 8.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.
Mirum Pharmaceuticals reported revenues of $111.58 million in the last reported quarter, representing a year-over-year change of +61.2%. EPS of -$0.30 for the same period compares with -$0.54 a year ago.
Mirum Pharmaceuticals is expected to post a loss of $0.32 per share for the current quarter, representing a year-over-year change of +38.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +3.8%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Mirum Pharmaceuticals. Also, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 40% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
At this time, Editas has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Mirum Pharmaceuticals, Inc. (MIRM - Free Report) , has gained 8.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.
Mirum Pharmaceuticals reported revenues of $111.58 million in the last reported quarter, representing a year-over-year change of +61.2%. EPS of -$0.30 for the same period compares with -$0.54 a year ago.
Mirum Pharmaceuticals is expected to post a loss of $0.32 per share for the current quarter, representing a year-over-year change of +38.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +3.8%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Mirum Pharmaceuticals. Also, the stock has a VGM Score of B.